Oncology Pipeline

For more than 50 years, Lilly has been dedicated to delivering life-changing medicines and support to people living with cancer and those who care for them. Lilly is determined to build on this heritage and continue making life better for all those affected by cancer around the world. In 2019 Lilly created Loxo Oncology at Lilly, with the goal of rapidly delivering impactful new medicines for people with cancer. Our approach centers on creating new medicines that work in early clinical development and will matter to patients.

KRAS G12C Inhibitor



Janes MR, et al1; Kano Y, et al2

KRAS is the most common oncogene across all tumor types. KRAS G12C represents a KRAS mutation in patients with non-small cell lung cancer (12% to 15%) and colorectal cancer (3%), and also occurs in patients with other solid tumors such as pancreatic cancer and endometrial cancer (1% to 2%).3,4
LY3537982 is a selective covalent inhibitor of KRAS G12C; it demonstrates activity as monotherapy and in combination with other anticancer therapies in preclinical models. It has competitive pharmacokinetic properties supporting its advancement into clinical testing. LY3537982 has been shown in vitro to target a KRAS G12C mutation, thereby inhibiting mutant KRAS-dependent signaling.
Clinical Development
LY3537982 is being studied in a clinical trial in patients with non-small cell lung cancer, colorectal cancer, or other advanced solid tumors.


  1. Janes MR, et al. Cell. 2018;172(3):578-589.
  2. Kano Y, et al. Nat Commun. 2019;10(1):224.
  3. Dogan S, et al. Clin Cancer Res. 2012;18(22):6169-6177.
  4. Jones RP, et al. Br J Cancer. 2017;116(7):923-929.

The safety and efficacy of the agents under investigation have not been established. There is no guarantee that the agents will receive regulatory approval and become commercially available for the uses being investigated.


BTK Inhibitor

Learn More

Selective ER Degrader

Learn More

PDGFRα Antibody

Learn More